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Effect of Screening Abdominal Ultrasound Examination on the
Decision to Pursue Advanced Diagnostic Tests and Treatment in
Dogs with Neurologic Disease
N.M. Tong, A.L. Zwingenberger, W.H. Blair, S.L. Taylor, R.X. Chen, and B.K. Sturges
Background: Abdominal ultrasound examinations (AUS) are commonly performed before advanced neurodiagnostics to
screen for diseases that might affect diagnostic plans and prognosis.
Objectives: Describe the type and frequency of abnormalities found by AUS in dogs presenting with a neurological condi-
tion, identify risk factors associated with abnormalities, and evaluate treatment decisions based on findings.
Animals: Seven hundred and fifty-nine hospitalized dogs.
Methods: Retrospective study. Medical records of dogs presented from 2007 to 2009 for neurologic disease were searched
for signalment, neuroanatomic localization, and AUS findings. Whether dogs had advanced neurodiagnostics and treatment
was analyzed.
Results: Fifty-eight percent of dogs had abnormal findings on AUS. Probability of abnormalities increased with age
(P < 0.001). Nondachshund breeds had higher probability of abnormal AUS than dachshunds (odds ratio [OR] = 1.87). Ele-
ven percent of dogs did not have advanced neurodiagnostics and in 1.3%, this was because of abnormal AUS. Dogs with
ultrasonographic abnormalities were less likely than dogs without to have advanced neurodiagnostics (OR = 0.3 [95% confi-
dence interval [CI]: 0.17, 0.52]), however, the probability of performing advanced diagnostics was high regardless of normal
(OR = 0.95 [95% CI: 0.92, 0.97]) or abnormal (OR = 0.85 [95% CI: 0.81, 0.88]) AUS. Treatment was more often pursued in
small dogs and less often in dogs with brain disease.
Conclusions and Clinical Importance: Findings from screening AUS had a small negative effect on the likelihood of pursu-
ing advanced neurodiagnostics. Although it should be included in the extracranial diagnostic workup in dogs with significant
history or physical examination abnormalities, AUS is considered a low-yield diagnostic test in young dogs and dachshunds.
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Before imaging the brain or spinal cord in dogs,complete blood count, serum biochemistry panel,
urinalysis, thoracic radiographs, and abdominal ultra-
sound examinations (AUS) are often performed to rule
out causes of neurologic disease originating from out-
side the central nervous system and to screen for condi-
tions that might affect the decision to pursue diagnosis
and treatment as well as the outcome of treatment. Sup-
posedly, fewer abnormalities are identified on AUS in
younger dogs presenting with neurologic disease in
comparison to geriatric neurologic dogs which more
often have comorbid disease conditions. However, these
apparent relationships have not been quantitatively
assessed. Compared with the large body of literature
from human medicine exploring the role of preoperative
testing,1–12 there are few veterinary studies13–18 evaluat-
ing the value of screening tests as a tool. To the
authors’ knowledge, there are no studies that evaluate
the role of an AUS in dogs with neurologic disease.
The core purpose of screening tests is to identify clini-
cally important conditions that could benefit the dog by
early detection, but for which a physical abnormality is
not necessarily expected based on clinical examina-
tion.10,19 The primary flaws of screening are overdiag-
nosis, false positive results, incidental findings, and
increased costs that do not lead to medical benefit.1
These troublesome outcomes cause anxiety, increase
exposure to risks associated with follow-up procedures,
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Abbreviations:
AUS abdominal ultrasound examination
CT computed tomography
MRI magnetic resonance imaging
CSF cerebrospinal fluid
C1-C5 neuroanatomic localization from first cervical to fifth
cervical segment
C6-T2 neuroanatomic localization from sixth cervical to
second thoracic segment
T3-L3 neuroanatomic localization from third thoracic to
third lumbar segment
L4-caudal neuroanatomic localization from fourth lumbar
segment to the caudal segments
CI confidence interval
OR odds ratio
Kg kilogram
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and could affect the decision to proceed with further
diagnostics and treatment to address the primary condi-
tion.2,4,5,7–9,18–20
When faced with the high cost of neurodiagnostics
and surgery, owners and clinicians alike might find
themselves questioning the risk-to-benefit ratio of per-
forming an AUS and the implications of significant
abnormalities being found. The objectives of this study
are to: (1) describe the type and frequency of abnormal-
ities found by AUS in dogs presenting with a neurologi-
cal condition, (2) quantitate the odds of an abnormality
being discovered on an AUS based on age, breed, and
neuroanatomic localization of the lesion, (3) evaluate
diagnostic and treatment decisions in light of the ultra-
sound findings and other covariates.
The hypothesis of the study was that in certain sub-
populations of dogs presenting with neurological dis-
ease, including young chondrodystrophic dogs, the
AUS is not likely to identify an abnormality that would
prevent the client from going forward with advanced
neurodiagnostics, and surgical treatment for their dog.
Materials and Methods
Medical records of dogs presented to the Neurology/Neurosur-
gery Service at the UC Davis William R. Pritchard Veterinary
Medical Teaching Hospital for a neurologic condition between the
years 2007 and 2009 were reviewed. This included internal and
external referrals. Dogs that had an AUS as part of medical
screening before planned advanced neurodiagnostics including ver-
tebral column radiographs, myelogram, computed tomography
(CT), magnetic resonance imaging (MRI) and cerebrospinal fluid
(CSF) analysis were included. The medical screening tests included
complete blood count, serum biochemistries, urinalysis, and tho-
racic radiographs. For dogs with multiple visits, only the first visit
was included in order meet independence assumptions for the sta-
tistical analyses.
Signalment data included age, weight, sex, and breed. Individ-
ual breeds were recorded and classified as dachshund or nondachs-
hund as well as chondrodystrophic or nonchondrodystrophic. To
the authors’ knowledge, there is no comprehensive list of chondro-
dystrophic breeds, so the existing literature was evaluated for
breeds that have been identified as chondrodystrophic or included
in studies of chondrodystrophic dog breeds,21–30 resulting in the
following list: dachshund (miniature, standard, long hair, wire
hair), Pekingese, West Highland white terrier, corgi, Japanese chin,
bassett hound, shih tzu, Lhasa apso, bichon frise, beagle, pug,
Boston terrier, Cavalier King Charles spaniel, French bulldog,
English bulldog, miniature schnauzer, Tibetan spaniel, Jack Rus-
sell terrier, miniature poodle, Yorkshire terrier, border terrier, co-
ton du tulear.
For all cases included in the study, the neurological examina-
tions had been performed by faculty-supervised neurology resi-
dents and board certified neurologists. The neuroanatomic
localizations based on the neurological examinations that were
noted in the medical record were recorded. The categories were
brain, neuroanatomic localization from first cervical to fifth cervi-
cal segment (C1-C5), neuroanatomic localization from sixth cervi-
cal to second thoracic segment (C6-T2), neuroanatomic
localization from third thoracic to third lumbar segment (T3-L3),
and neuroanatomic localization from fourth lumbar segment to
the caudal segments (L4-caudal). All AUS had been performed
and reports written by faculty-supervised radiology residents and
board certified radiologists. The reports were reviewed retrospec-
tively and if an abnormality was identified in the report, the
abnormal organ system was recorded (liver, spleen, urinary, gas-
trointestinal, adrenal, lymph nodes, pancreas, reproductive), and
categorized according to one of the following descriptors: nodule/
mass, degenerative change, inflammation, enlargement, reduction
in size, mineralization, hypoechoic, hyperechoic, or other. In those
dogs that had a nodule or mass identified, the maximum dimen-
sion based on ultrasound images was recorded. If cytology or his-
topathology had been performed on the ultrasonographically
abnormal organ, the results were recorded as well. Dogs were then
categorized according to which, if any, advanced diagnostics were
performed (vertebral column study, myelogram, CT, MRI, CSF
analysis). The decision to treat medically or surgically, to not
treat, or to euthanize was recorded. For those that were not trea-
ted, the primary reason was noted and assigned to one of the fol-
lowing categories: declined by owner, improved with conservative
management, abnormal AUS findings, other disease, or increased
anesthetic risk preventing safe performance of the neurological dis-
ease workup, unknown, died, or other. Clients who failed to fol-
low up on recommendations for advanced neurodiagnostics or did
not show for scheduled procedures were included in the “declined
by owner” category.
Logistic regression analysis was used to identify significant pre-
dictors of the probability of a dog having an abnormal ultrasound
result. The effects of demographic predictors consisting of age,
weight, sex, and breed type were considered first. Then the rela-
tionship between the probability of an abnormal ultrasound and
the neuroanatomic localization of the lesion was evaluated. Age
groups were 0–6 years, >6–12 years, and >12 years. Weight groups
were 0–10 kg, >10–25 kg, and >25 kg. As noted previously, breed
type was classified into chondrodystrophic or nonchondrody-
strophic breeds, and dachshund or nondachshund breeds.
For significant main effects, Tukey’s Honestly Significant Differ-
ences method was used to identify significant group differences
while maintaining the family-wise type I error at 0.05. A Chi-
square test was used to determine whether conducting advanced
neurologic diagnostics was associated with the presence of an
abnormal ultrasound. Logistic regression also was used to model
the probability that a neurologic disorder was treated as a func-
tion of age group, occurrence of an abnormal ultrasound, and the
location of the neurologic disorder.
Results
Seven hundred and fifty-nine dogs met inclusion crite-
ria, consisting of 324 (42.7%) females and 435 (57.3%)
males. Three hundred and eighteen (41.9%) dogs were
classified as chondrodystrophic breeds and 441 (58.1%)
as nonchondrodystrophic breeds. Recategorizing the
same 759 dogs, there were 139 (18.3%) dachshunds and
620 (81.6%) nondachshund breeds. Dachshund breeds,
therefore, comprised 43.7% (139/318) of the total chon-
drodystrophic population. Age was recorded for 754
dogs (99.3%) ranging from 0.27 to 17 years old. Weight
was recorded for 665 animals (87.6%), ranging from
0.66 to 90.4 kg. Of the 759 dogs studied, 444 (58.5%)
had abnormal ultrasound examinations and 315
(41.5%) had normal examinations. Most dogs (675,
88.9%) underwent advanced neurodiagnostic proce-
dures.
The probability of abnormal AUS examination
findings increased with age (P < 0.0001). The mean
probability of detecting an ultrasonographic abnormal-
ity for the 0–6 year old age group was 0.42 (95% confi-
dence interval [CI] 0.36–0.49). For the >6–12 year
old age group the mean probability was 0.65 (95% CI
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0.60–0.70), and for the >12–17 year old age group it
was 0.93 (95% CI 0.84–0.97). Other demographic vari-
ables evaluated (sex, weight, chondrodystrophic versus
nonchondrodystrophic breed) were not significant, with
the exception that dogs weighing between 10–25 kg had
a higher probability of an abnormal AUS finding than
dogs weighing <10 kg (P = 0.04) (Table 1).
We then considered the effect of the location of the
neurologic lesion on the probability of a dog having an
abnormal AUS with inclusion of age and weight as co-
variates. Age remained significant in this modeling
(P < 0.001), but weight and neuroanatomic localization
of disease were not significant predictors of the proba-
bility of a dog having an abnormal AUS finding.
Logistic regression was used to evaluate the probabil-
ity of an abnormal AUS for dachshunds versus other
breeds. Fifty-nine of 139 dachshunds (42.4%) and 385/
620 nondachshunds (62.1%) had an abnormality identi-
fied on AUS. Age and dachshund versus nondachshund
breed status were significant predictors of whether a
dog had an abnormal AUS (P < 0.001 and P = 0.012,
respectively). Among dachshunds, all age groups dif-
fered significantly from each other, showing again by
virtue of increasing odds ratios (OR) with age, that the
probability of an abnormal AUS examination increased
with age (Table 1). Nondachshunds had higher proba-
bility of having an abnormal AUS than dachshunds
(P = 0.01, OR = 1.87) after accounting for age as a fac-
tor.
In the 444 dogs with an abnormal AUS, 1,184 ultra-
sound abnormalities were identified; the abnormal
organ system involved and the abnormal ultrasound
characteristic were tabulated (Table 2). In total, 844
organ systems were affected: the urinary tract (220),
liver (186), spleen (153), adrenal glands (81), reproduc-
tive system (60), other (48), lymph node (37), pancreas
(30), and gastrointestinal tract (29). In these affected
organ systems, 1,184 abnormalities were identified:
enlargement (312), other (249), nodule/mass (175),
hyperechoic (157), hypoechoic (107), degenerative
change (74), mineralized (69), reduction in size (29),
inflammation (12). The five most common combinations
of organ and abnormality were urinary + other (126),
liver + enlargement (110), spleen + nodule (78), liver +
hyperechoic (64), spleen + enlargement (62).
The decision to pursue advanced neurodiagnostics
was significantly associated with an abnormal AUS
finding (P < 0.001). The OR of conducting advanced
testing for dogs with an abnormal ultrasound versus
those with a normal ultrasound was 0.30 (95% CI:
0.17, 0.52), indicating that the presence of abnormalities
reduced the likelihood of conducting advanced testing.
However, the probability of a dog undergoing advanced
testing was high regardless of whether the ultrasound
revealed an abnormality. The estimated probability of
advanced testing being conducted for dogs with abnor-
mal AUS was 0.85 (95% CI: 0.81 and 0.88) versus 0.95
(95% CI: 0.92 and 0.97) for dogs with normal results.
The type of abnormality did not significantly influence
whether advanced neurologic testing was performed.
The most common reason among the 85 dogs that
did not have advanced diagnostics performed was
“Declined by owner” (29/85 = 34%). “Improvement
with conservative management” was the second most
common reason (20/85 = 23%), followed by “Other dis-
ease conditions or anesthetic risks” (17/85 = 20%). The
findings from an abnormal AUS examination were the
primary reason for not pursuing further neurodiagnos-
tics in 10/85 (11%) dogs, constituting 1.3% of the total
study population. In the subpopulation of dogs that did
not have advanced diagnostics because of the abnormal
findings from AUS, the most significant ultrasono-
graphically abnormal organ systems affected were: liver
(3), spleen (3), lymph node (1), reproductive tract (1),
adrenal glands (2). The histopathologic, cytologic, or
presumptive diagnoses were identified from the medical
records. Of these dogs with the most significant abnor-
mality identified in the liver, two had an enlarged liver
with nodules—the first was diagnosed with hepatocellu-
lar carcinoma (based on histopathology) and the second
Table 1. Pairwise comparisons from logistic regres-
sions of the likelihood of ultrasound abnormalities
between age groups and between weight groups with
Tukey–Kramer Adjustment (Adj P).
Group 1 Group 2 Adj P OR
Age groups (years) (12, 17) (6, 12] <0.001* 6.9
(12, 17] [0, 6] <0.001* 17.8
(6, 12] [0, 6] <0.001* 2.6
Weight groups (kg) (10, 25] (25, 81] 0.734 1.2
(10, 25] [0, 10] 0.0311* 1.8
(25, 81] [0, 10] 0.285 1.5
Age groups (years),
dachshunds only
(12, 17) (6, 12] <0.001* 6.5
(12, 17] [0, 6] <0.001* 16.3
(6, 12] [0, 6] <0.001* 2.5
Adj P, adjusted P-value. OR, odds ratio.
Odds of an ultrasound abnormality were higher in the older age
groups. Dogs were divided into the following age groups:
0–6 years old, >6–12 years old, >12–17 years old. The weight
groups were 0–10 kg, >10–25 kg, >25–81 kg.
Asterisks denote significant difference between groups.
Table 2. Screening ultrasonographic abnormalities
among all dogs.
E HO HR M N OT R
A 54 1 2 0 24 1 9
G 1 2 3 0 1 23 0
L 110 29 64 1 37 39 13
LN 32 10 0 0 0 3 1
OT 1 4 7 0 14 28 0
P 13 6 11 0 4 7 0
R 37 3 15 10 6 20 0
S 62 51 23 0 78 14 0
U 2 1 32 58 11 200 6
Ultrasound abnormalities (rows): E, enlargement; HO, hypo-
echoic; HR, hyperechoic; M, mineralization; N, nodule/mass; OT,
other; R, reduction in size, NA, not available. Organ systems (col-
umns): A, adrenal gland; G, gastrointestinal; L, liver, LN, lymph
node; P, pancreas; R, reproductive; S, spleen; U, urinary.
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had a suppurative hepatitis (based on cytology). The
third dog with liver changes had nodules that were
diagnosed as lymphoma (histopathology). Splenic nod-
ules were present in two of the dogs that did not have
advanced diagnostics. One had histiocytic sarcoma
(cytologic and histopathologic diagnosis), and two had
presumptive hemangiosarcoma (hemoabdomen with
splenic and hepatic nodules identified in one dog, previ-
ous history of histopathologically diagnosed vertebral
hemangiosarcoma in the second dog). One dog with
enlarged lymph nodes had a cytologic diagnosis of his-
tiocytic sarcoma. One dog with prostatic enlargement,
nodules and mineralization had a cytologic diagnosis of
prostatic transitional cell carcinoma followed by histo-
pathologic confirmation. Two dogs had an adrenal nod-
ule/mass that had no histopathologic or cytologic
diagnosis, but were presumed malignancies because of
vascular invasion.
Factors influencing decisions to treat a neurological
disease were investigated. Neither age nor abnormal
AUS findings were significant predictors of the decision
of whether to treat a neurological disease. However,
weight was a significant predictor of not treating a dis-
ease (P = 0.015–0.035, depending on the lesion localiza-
tion). Compared with small dogs (under 10 kg), larger
dogs had a lower probability of being treated
(OR = 0.37–0.42, P = 0.01–0.05; variation based on
neuroanatomic localization). In addition, the neuroan-
atomic location of disease, either in the brain or the
C6-T2 spinal cord segment was associated with the
probability of treating the dog. The estimated probabil-
ity of treating a C6-T2 localization was higher (0.93
[95% CI: 0.84 and 0.97]) than for other spinal cord
localizations collectively (0.81 [95% CI: 0.71 and 0.89]).
The estimated probability of treating a dog with neuro-
logical disease localizing to the brain was lower (0.54
[95% CI: 0.27 and 0.78]) than for all other neuroan-
atomic localizations collectively (0.85 [95% CI: 0.75 and
0.91]).
Discussion
The majority of dogs in the study population had an
abnormality identified on AUS and these dogs were less
likely to go on to advanced neurodiagnostics than those
with normal AUS. However, overall, the probability of
moving forward with advanced neurodiagnostics was
high regardless of a normal or abnormal AUS. As
hypothesized, young dogs and dachshunds were less
likely to have an abnormal AUS; surprisingly, chondro-
dystrophic breeds as a group were not. The percentage
of dogs that did not move on to advanced neurodiag-
nostics primarily because of AUS findings was quite
small, suggesting a limited effect of the abnormal find-
ings on the decisions to proceed with advanced diagnos-
tics and treatment.
The AUS for neurological dogs serves a dual role of
identifying an intra-abdominal cause of the neurological
disease and to screen for the presence of concurrent,
undiagnosed disease. Our study’s finding that older
dogs have a higher likelihood of AUS abnormalities
parallels the findings of several prospective human and
veterinary studies15,16,20,31,32 and, when applied to older
dogs, adds strength to the recommendation that AUS
should be performed to look for extracranial neoplasia
before advanced imaging of the brain or intracranial
surgery.33 The costs and risks associated with AUS in
these dogs can be justified since it is sensitive for detec-
tion of intra-abdominal abnormalities, but because the
ultrasonographic changes are rarely specific for disease
etiology, biologic sampling is required for diagnosis.
Young dogs and dachshunds presenting with neuro-
logic disease are less likely to have an abnormal AUS
compared with others. This suggests relatively lower
intra-abdominal disease prevalence in these two groups.
When disease prevalence is low, there is higher likeli-
hood of false positive results. If the incidental abnormal
AUS findings in these dogs are more likely to be false
positives or of low clinical significance, the risks associ-
ated with follow-up testing for these types of findings—
complications from invasive procedures (biopsy, sur-
gery, endoscopy), increased stress to the owner and dog
and increased costs that do not lead to medical benefit
—might not be worth assuming. As such, a routine
screening AUS could be considered a less critical com-
ponent of the extracranial workup for a young dog or
dachshund presenting for neurologic signs. At the very
least, owners of these dogs should be advised before-
hand that the abdominal ultrasound exam is likely to
be low yield and could identify incidental abnormalities.
Although dachshunds as a group and chondrody-
strophics as a group share an increased risk of interver-
tebral disk herniation at a young age,28,29 our study
demonstrated they do not share a decreased risk of hav-
ing abnormal AUS findings. Early investigations into
the tendency of some breeds to intervertebral disk dis-
ease identified only the dachshund, Pekinese, and
French bulldogs as a “chondrodystrophoid breed
group.”34 Furthermore, the correlation between chondr-
odystrophy and intervertebral disk disease has not been
established for all breeds.29 The list of breeds catego-
rized as chondrodystrophic for this study was collated
from lists from many publications that spanned several
decades, since universal agreement on this is lacking.
Perhaps inclusion of so many breeds in the chondrody-
strophic group negated the protective effect of the
dachshunds.
Although the likelihood of a dog with an abnormal
AUS proceeding to advanced neurodiagnostics was
lower than a dog with a normal AUS, the overall likeli-
hood that a dog with an abnormal AUS had advanced
neurodiagnostics was still quite high. This is most likely
because of the tertiary referral institution population
studied. Clients presenting to our referral institution are
more willing to proceed with advanced neurodiagnostics
despite an abnormal AUS finding, which could bias our
study population and results. Whether a willingness to
proceed with advanced diagnostics and treatment would
hold true in a nontertiary referral practice remains to
be determined.
In a study of 53 mature, healthy golden retriev-
ers undergoing screening AUS, 64.2% had AUS
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abnormalities.18 Two studies have explored the role of
AUS before treatment for oncologic disease. Fifty seven
percent of 118 dogs diagnosed with osteosarcoma had
AUS abnormalities,17 while among 101 dogs who were
candidates for radiation therapy because of diagnosis of
one of three different types of neoplasms with low met-
astatic potential (soft tissue sarcoma, primary brain
tumor, intranasal tumors) there was a 78–87% fre-
quency of abnormal AUS.14 Our study’s finding of a
frequency of 58% of AUS abnormalities is similar to
these three studies, and strengthened by our large study
population.
Although not direct comparisons to the aforemen-
tioned studies, our study’s finding of 1.3% of the study
population not moving on to advanced neurodiagnos-
tics primarily because of abnormal AUS findings is
lower than the rates of 6.4% for the frequency of AUS
abnormalities deemed capable of changing the progno-
sis or therapeutic recommendations in dogs with osteo-
sarcoma, and 9% for serious comorbidities identified by
thoracic radiographs, AUS, or both that resulted in
alteration in treatment plans in dogs with neoplasms
with low metastatic potential. Perhaps the reason why
our study had such low percentage of cases with the
diagnostic or treatment plan altered by AUS findings
was the categorization scheme we used. Retrospectively
categorizing the rationale for why advanced neurodiag-
nostics and treatment were not pursued is difficult, as
the reasons are often multifactorial. It is possible that a
fair number of the cases in our study, where advanced
neurodiagnostics and treatment were “declined by
owner” were because of significant comorbidities identi-
fied on abdominal ultrasound, but was not clearly
expressed as such by the owner or in the medical
record.
In evaluating the role of the screening AUS on likeli-
hood of proceeding to advanced neurodiagnostics and
treatment, another parallel is the routine preanesthetic
blood work. No consensus opinion on the utility of pre-
anesthetic screening in dogs has been reached, but in a
large-scale retrospective study of 1,537 dogs, the
changes revealed by preoperative hematologic and bio-
chemical screening rarely prompted major changes to
anesthetic technique. The authors of the study con-
cluded that in dogs without abnormalities identified in
careful clinical history taking or physical examination,
the screening preanesthetic blood work is often clini-
cally irrelevant.13 This is similar to the literature in
human medicine, where multiple studies have shown
and many reviews and guidelines state that routine pre-
operative screening tests are of questionable benefit,
and rarely change anesthetic management or improve
surgical outcome for human surgery patients. Rather,
decisions about ordering selective or directed preopera-
tive tests should be guided by the clinical history, physi-
cal exam findings, and comorbid conditions.1–3,7–11,35
We propose that similar logic should be employed in
determining the necessity of the AUS in neurological
dogs before advanced imaging and treatment.
Those smaller dogs were more likely to be treated
than larger dogs could be because of the fact that
smaller dogs with neurologic dysfunction would be less
difficult for the client to manage at home than larger
dogs and the difference in differential diagnoses and
associated prognoses for small versus large breed dogs.
The fact that the brain was treated surgically less often
than lesions in other neuroanatomic localizations might
be because of the nature of the disease, the invasiveness
of the treatment procedures, potential complications,
high cost, and variable prognoses based on lesion type
and location. Somewhat surprisingly, we found C6-T2
lesions were more likely to be treated surgically than
lesions with other neurolocalizations even though inter-
vertebral disk extrusions are most common in the cervi-
cal and T11-L3 regions. This could be because of the
comparative severity of myelopathic signs seen in the
C6-T2 region versus the T3-caudal segments with inter-
vertebral disk disease. Complete paralysis and loss of
pain sensation are neurological findings that are associ-
ated with a guarded to poor prognosis for recovery.36
These clinical signs are rare neurological findings in
lesions affecting the cervical spinal cord, whereas they
are commonly seen in the T3-L3 region of the spinal
cord. Owners given an overall poorer prognosis for
recovery based on the neurological signs of paralysis
and loss of pain sensation might be less likely to move
forward with diagnosis and treatment. Also, the inclu-
sion of dogs with suspected degenerative myelopathy,
which characteristically presents with signs of T3-L3
myelopathy and has no MRI changes or specific treat-
ment,37 could have negatively affected the percentage of
dogs with T3-L3 myelopathy that are treated.
The primary limitation of this study is the retrospec-
tive nature. Although certain assumptions and interpre-
tations had to be made from the medical records and
were unavoidable, these were kept to a minimum by
limiting the amount of data that were collected and
using a systematic approach to categorization. Including
dogs which were internal referrals within the hospital
could have included a population, that is, less likely to
pursue advanced neurodiagnostics because of other
more critical medical conditions that require attention
first. This internal referral population could also have
biased the results toward more abnormal AUS examin-
ations. Although some degree of error and bias is inher-
ent in retrospective studies, this might be minimized by
the large number of dogs reported in this study. Also,
while ultrasonography is sensitive for lesion detection,
the changes are rarely specific for disease etiology.38 A
prospective study with histopathologic correlation for
abnormal AUS findings could better elucidate the effect
of the findings on further diagnostics and treatment,
but is impractical, as there is little justification for
biopsy specimen collection in dogs with no clinical signs
associated with the AUS finding.
In summary, abnormal findings from screening AUS
had a small negative effect on the likelihood of pursuing
advanced neurodiagnostics. The use of AUS as a direc-
ted preoperative test in dogs with historical or physical
examination data that suggest an intra-abdominal co-
morbid condition or potential cause of the neurologic
signs should still be performed, particularly in older
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dogs, but an AUS is a low-yield screening test for neu-
rological young dogs and dachshunds. These data could
help clinicians and clients in their decision-making pro-
cess as to whether the AUS is included as part of a
diagnostic evaluation before advanced neurodiagnostics
and treatment.
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